Search

Displaying results 5281 - 5290 of 9333 in total
  1. Drug

    5-(5-(4-(5-hydro-4-methyl-2-oxazolyl)phenoxy)pentyl)-3-methyl isoxazole

    go.drugbank.com/drugs/DB08724
    Experimental

    This compound belongs to the phenol ethers. These are aromatic compounds containing an ether group substituted with a benzene ring. This medication is known to target genome polyprotein.

  2. Drug

    Fluciclatide

    go.drugbank.com/drugs/DB14842
    Investigational

    Fluciclatide, an investigational radiotracer intended for PET imaging, was under investigation in clinical trials NCT00565721 and NCT01961583 to evaluate its ability to detect tumors and angiogenesis. … The conditions targeted by [18F]Fluciclatide in these studies include high-grade glioma, lung cancer, and kidney neoplasms

  3. Drug

    Elsubrutinib

    go.drugbank.com/drugs/DB18850
    Investigational

    With Moderately to Severely Active Systemic Lupus Erythematosus to Assess Change in Disease State). … Elsubrutinib is under investigation in clinical trial NCT04451772 (A Study of the Safety of Oral Elsubrutinib Capsules and Oral Upadacitinib Tablets Given Alone or in Combination (ABBV-599) for Adult Participants

  4. Drug

    Golotimod

    go.drugbank.com/drugs/DB05475
    Investigational

    It has been shown to stimulate T-lymphocyte differentiation, macrocytic phagocytosis, and specific immune responses, and enhance IL-2 and INF-g production. … Due to this preferential activation of Th1 cytokine production, SCV-07 may show utility in treatment of tuberculosis. It can be administered orally or subcutaneously.

  5. Drug

    GX-19 Vaccine

    go.drugbank.com/drugs/DB15891
    Investigational

    As of June 2020, the vaccine candidate is undergoing Phase I and Phase IIa trials to determine dose levels for safety and efficacy[A219758,L16488]. … The GX-19 vaccine is a DNA vaccine created by Genexine, Inc. Company in Gyeonggi, Korea[A219758].

  6. Drug

    Oportuzumab monatox

    go.drugbank.com/drugs/DB05319
    Investigational

    VB4-845 is studied in the treatment of certain types of head and neck cancer. VB4-845 is made by linking a monoclonal antibody fragment to a toxic protein that may kill cancer cells. … VB4-845 is a fusion protein containing humanized scFv specific for the epithelial cell adhesion molecule, Ep-CAM, a tumor cell-associated target highly expressed on carcinoma cells of epithelial origin

  7. Drug

    Bleomycin A6

    go.drugbank.com/drugs/DB12992
    Investigational

    It was shown that besides the antitumor effect, Bleomycin A6 had the ability to alter the tumor microenvironment and could contribute toward lung cancer relapse and metastasis on long-term treatment. … The development of this drug, apparently, was discontinued.

  8. Drug

    AGuIX

    go.drugbank.com/drugs/DB18189
    Investigational

    It is under development as a radiosensitizer to be used during radiation treatment of malignant glioma.

  9. Drug

    Pacmilimab

    go.drugbank.com/drugs/DB18873
    Investigational

    Pacmilimab is under investigation in clinical trial NCT04596150 (Study to Evaluate the Safety and Antitumor Activity of CX-2009 Monotherapy and in Combination With CX-072 in Advanced Breast Cancer).

  10. Drug

    ABT-639

    go.drugbank.com/drugs/DB15055
    Investigational

    ABT-639 is under investigation in clinical trial NCT01345045 (A Multicenter Study Comparing the Analgesic Effects and Safety of ABT-639 Compared to Placebo in Subjects With Diabetic Neuropathic Pain).